TENX — Tenax Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $245.93m
- $148.36m
Annual cashflow statement for Tenax Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.5 | -11 | -7.71 | -17.6 | -52.6 |
| Depreciation | |||||
| Non-Cash Items | 22.2 | 0.471 | 0.192 | 1.13 | 19.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.609 | -1.44 | 1.61 | 1.67 | -2.36 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -10.9 | -12 | -5.9 | -14.8 | -35.8 |
| Capital Expenditures | -0.005 | -0.002 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.458 | 0 | 0.003 | 0 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.453 | -0.002 | 0.003 | 0 | — |
| Financing Cash Flow Items | — | 7.93 | 14.2 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.74 | 8.55 | 13.6 | 99.9 | 38.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.666 | -3.46 | 7.67 | 85.1 | 2.71 |